The utility of CRP with the use of dexamethasone and Tocilizumab in critically ill patients with COVID-19

J Crit Care. 2022 Aug:70:154053. doi: 10.1016/j.jcrc.2022.154053. Epub 2022 May 12.

Authors

Harry Zacharias¹, Ritwik Mungara¹, Andrew Peter Wilson², Mervyn Singer¹, Nishkantha Arulkumaran³

Affiliations

¹ Bloomsbury Institute for Intensive Care Medicine, University College London, London, United Kingdom.
² Department of Clinical Microbiology, University College London NHS Foundation Trust, London, United Kingdom.
³ Bloomsbury Institute for Intensive Care Medicine, University College London, London, United Kingdom. Electronic address: nisharulkumaran@doctors.org.uk.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized
COVID-19 Drug Treatment*
Critical Illness
Dexamethasone / therapeutic use
Humans

Substances

Antibodies, Monoclonal, Humanized
Dexamethasone
tocilizumab